{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:32:56Z","timestamp":1792737176157,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.mcna.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T12:20:03Z","timestamp":1622204403000},"page":"611-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Diagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas"],"prefix":"10.1016","volume":"105","author":[{"given":"Cynthia X.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Zug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2021.04.003_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.003_bib2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamadermatol.2017.3046","article-title":"Consumer preferences, product characteristics, and potentially allergenic ingredients in best-selling moisturizers","volume":"153","author":"Xu","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib3","first-page":"e13017","article-title":"The benefit of a ceramide-linoleic acid-containing moisturizer as an adjunctive therapy for a set of xerotic dermatoses","volume":"32","author":"Yang","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2340\/00015555-2882","article-title":"Stand-alone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis: a double-blind, randomized, vehicle-controlled, left-right comparison study","volume":"98","author":"Angelova-Fischer","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.003_bib5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2340\/00015555-2395","article-title":"Efficacy of a cream containing ceramides and magnesium in the treatment of mild to moderate atopic dermatitis: a randomized, double-blind, emollient- and hydrocortisone-controlled trial","volume":"96","author":"Koppes","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2021.04.003_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2005.01.032","article-title":"Topical drug classification","volume":"295","author":"Buhse","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.mcna.2021.04.003_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2133.2006.07538.x","article-title":"A\u00a0systematic review of the safety of topical therapies for atopic dermatitis","volume":"156","author":"Callen","year":"2007","journal-title":"Br J Dermatol"},{"issue":"47","key":"10.1016\/j.mcna.2021.04.003_bib9","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8470","article-title":"Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation","volume":"8","author":"Green","year":"2004","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.003_bib10","first-page":"243","article-title":"Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream","volume":"16","author":"Zirwas","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: A review","volume":"82","author":"Avila","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.003_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10247","key":"10.1016\/j.mcna.2021.04.003_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.003_bib14","first-page":"CD004054","article-title":"Psychological and educational interventions for atopic eczema in children","volume":"2014","author":"Ersser","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.003_bib15","first-page":"CD003871","article-title":"Interventions to reduce Staphylococcus aureus in the management of eczema","volume":"2019","author":"George","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.003_bib16","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1468-3083.2007.02277.x","article-title":"The effect of wet-wrap dressing on epidermal barrier in patients with atopic dermatitis","volume":"21","author":"Lee","year":"2007","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.003_bib17","first-page":"CD012119","article-title":"Emollients and moisturisers for eczema","volume":"2","author":"van Zuuren","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.003_bib18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","article-title":"Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib20","article-title":"Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus","author":"Luger","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.mcna.2021.04.003_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"330","author":"Ashcroft","year":"2005","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.003_bib22","first-page":"CD009864","article-title":"Topical tacrolimus for atopic dermatitis","volume":"2015","author":"Cury Martins","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2 Suppl 2","key":"10.1016\/j.mcna.2021.04.003_bib23","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.jaad.2005.04.061","article-title":"Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis","volume":"53","author":"Chapman","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.003_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CLEP.S146442","article-title":"A\u00a0cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)","volume":"10","author":"Castellsague","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.003_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2133.2009.09145.x","article-title":"Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial","volume":"161","author":"Leung","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.003_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to\u2009<\u200924 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)","volume":"21","author":"Schlessinger","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.003_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000246198","article-title":"Out-patient treatment of atopic dermatitis with crude coal tar","volume":"193","author":"van der Valk","year":"1996","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.003_bib30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2133.1989.tb08219.x","article-title":"A\u00a0comparative trial of Clinitar versus hydrocortisone cream in the treatment of atopic eczema","volume":"121","author":"Munkvad","year":"1989","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.mcna.2021.04.003_bib31","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.mcna.2021.04.003_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjd.12645","article-title":"Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research","volume":"170","author":"Garritsen","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.mcna.2021.04.003_bib34","first-page":"CD013206","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"2020","author":"Sawangjit","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2021.04.003_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.mcna.2021.04.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic immunomodulatory treatments for patients with atopic dermatitis. A systemic review and network meta-analysis","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2018.09.053","article-title":"Relative efficacy of systemic treatments for atopic dermatitis","volume":"80","author":"Seger","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.003_bib39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2009.09561.x","article-title":"Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial","volume":"162","author":"Schmitt","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/ITT.S229667","article-title":"Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis","volume":"9","author":"Singh","year":"2020","journal-title":"Immunotargets Ther"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1600-0536.1984.tb01010.x","article-title":"Prediction of patch test results","volume":"11","author":"Podmore","year":"1984","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cod.13322","article-title":"New positive patch test reactions on day 7-The additional value of the day 7 patch test reading","volume":"81","author":"van Amerongen","year":"2019","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/DER.0000000000000297","article-title":"Delayed patch-test reading after 5\u00a0days: an update from the mayo clinic contact dermatitis group","volume":"28","author":"Chaudhry","year":"2017","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.003_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/DER.0000000000000417","article-title":"North American contact dermatitis group patch test results: 2015-2016","volume":"29","author":"DeKoven","year":"2018","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.003_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0536.2000.043001001.x","article-title":"Use tests: ROAT (repeated open application test)\/PUT (provocative use test): an overview","volume":"43","author":"Nakada","year":"2000","journal-title":"Contact Dermatitis"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2005.04.075","article-title":"A\u00a0systematic review of contact dermatitis treatment and prevention","volume":"53","author":"Saary","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.003_bib48","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1111\/ijd.12641","article-title":"Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach","volume":"53","author":"Han","year":"2014","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1468-3083.2008.03056.x","article-title":"Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis","volume":"23","author":"Katsarou","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.003_bib50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2500\/aap.2006.27.2915","article-title":"Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis","volume":"27","author":"Pacor","year":"2006","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.003_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2006.03.025","article-title":"A\u00a0prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis","volume":"55","author":"Belsito","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.003_bib52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1067\/S0190-9622(03)01826-7","article-title":"Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis","volume":"49","author":"Saripalli","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.003_bib53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2133.2004.05724.x","article-title":"Narrowband ultraviolet B in airborne contact dermatitis: a ray of hope!","volume":"150","author":"Dogra","year":"2004","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib54","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1396-0296.2004.04031.x","article-title":"Treatment of irritant and allergic contact dermatitis","volume":"17","author":"Cohen","year":"2004","journal-title":"Dermatol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2021.04.003_bib55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jdv.16061","article-title":"Hand eczema: epidemiology, prognosis and prevention","volume":"34","author":"Agner","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"19","key":"10.1016\/j.mcna.2021.04.003_bib56","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJMcp1104084","article-title":"Hand eczema","volume":"367","author":"Coenraads","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.04.003_bib57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2133.2008.08907.x","article-title":"Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema","volume":"160","author":"Diepgen","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib58","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jdv.12735","article-title":"Patch test results of hand eczema patients: relation to clinical types","volume":"29","author":"Boonstra","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2021.04.003_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jdv.16062","article-title":"Hand eczema: treatment","volume":"34","author":"Elsner","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib60","first-page":"CD004055","article-title":"Interventions for hand eczema","volume":"4","author":"Christoffers","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.003_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjd.16238","article-title":"An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema","volume":"179","author":"Brass","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.003_bib62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/1346-8138.15344","article-title":"Botulinum toxin type A in chronic non-dyshidrotic palmar eczema: A side-by-side comparative study","volume":"47","author":"Ismail","year":"2020","journal-title":"J\u00a0Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mjd.2002.124605","article-title":"Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin","volume":"47","author":"Swartling","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2021.04.003_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1468-3083.2002.00361.x","article-title":"Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison","volume":"16","author":"Wollina","year":"2002","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.003_bib65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2133.2003.05729.x","article-title":"Novel treatment of chronic severe hand dermatitis with bexarotene gel","volume":"150","author":"Hanifin","year":"2004","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.003_bib66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5021\/ad.2017.29.3.385","article-title":"Acitretin as a Therapeutic Option for Chronic Hand Eczema","volume":"29","author":"Song","year":"2017","journal-title":"Ann Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib67","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/jdv.16088","article-title":"Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis","volume":"34","author":"Luchsinger","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.003_bib68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1468-3083.2006.01879.x","article-title":"Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients","volume":"21","author":"Schulz","year":"2007","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.003_bib69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/DER.0b013e318260d5a0","article-title":"Nummular eczema and contact allergy: a retrospective study","volume":"23","author":"Bonamonte","year":"2012","journal-title":"Dermatitis"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.003_bib70","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jaad.2019.12.054","article-title":"Dupilumab treatment of nummular dermatitis: A retrospective cohort study","volume":"82","author":"Choi","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:23:49Z","timestamp":1710458629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712521000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0025712521000419"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2021.04.003","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}